Pulsed electromagnetic field applications: A corporate perspective
Corporate establishment of US Food & Drug Administration approved pulsed electromagnetic fields (PEMFs) for clinical applications has been achieved. However, optimization of PEMFs for improvement in efficacy for current indications, in addition to the expansion into new indications, is not trivi...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-04-01
|
Series: | Journal of Orthopaedic Translation |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214031X16302790 |
id |
doaj-f238c173a1f449ae8ba309991e5771b4 |
---|---|
record_format |
Article |
spelling |
doaj-f238c173a1f449ae8ba309991e5771b42020-11-25T01:19:13ZengElsevierJournal of Orthopaedic Translation2214-031X2017-04-019C606810.1016/j.jot.2017.02.006Pulsed electromagnetic field applications: A corporate perspectiveErik I. WaldorffNianli ZhangJames T. RyabyCorporate establishment of US Food & Drug Administration approved pulsed electromagnetic fields (PEMFs) for clinical applications has been achieved. However, optimization of PEMFs for improvement in efficacy for current indications, in addition to the expansion into new indications, is not trivial. Moving directly into a clinical trial can be costly and carries little guarantee for success, necessitating the need for preclinical studies as supported by this review of the extensive corporate preclinical experience by Orthofix, Inc. The Translational Potential of this Article: This review illustrates the need to gain enough in vitro/in vivo knowledge of specific PEMF signals and its target tissue interaction to enable a high success rate in clinical trials.http://www.sciencedirect.com/science/article/pii/S2214031X16302790electromagnetic fieldelectromagnetic wavemagnetic field therapies |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Erik I. Waldorff Nianli Zhang James T. Ryaby |
spellingShingle |
Erik I. Waldorff Nianli Zhang James T. Ryaby Pulsed electromagnetic field applications: A corporate perspective Journal of Orthopaedic Translation electromagnetic field electromagnetic wave magnetic field therapies |
author_facet |
Erik I. Waldorff Nianli Zhang James T. Ryaby |
author_sort |
Erik I. Waldorff |
title |
Pulsed electromagnetic field applications: A corporate perspective |
title_short |
Pulsed electromagnetic field applications: A corporate perspective |
title_full |
Pulsed electromagnetic field applications: A corporate perspective |
title_fullStr |
Pulsed electromagnetic field applications: A corporate perspective |
title_full_unstemmed |
Pulsed electromagnetic field applications: A corporate perspective |
title_sort |
pulsed electromagnetic field applications: a corporate perspective |
publisher |
Elsevier |
series |
Journal of Orthopaedic Translation |
issn |
2214-031X |
publishDate |
2017-04-01 |
description |
Corporate establishment of US Food & Drug Administration approved pulsed electromagnetic fields (PEMFs) for clinical applications has been achieved. However, optimization of PEMFs for improvement in efficacy for current indications, in addition to the expansion into new indications, is not trivial. Moving directly into a clinical trial can be costly and carries little guarantee for success, necessitating the need for preclinical studies as supported by this review of the extensive corporate preclinical experience by Orthofix, Inc.
The Translational Potential of this Article: This review illustrates the need to gain enough in vitro/in vivo knowledge of specific PEMF signals and its target tissue interaction to enable a high success rate in clinical trials. |
topic |
electromagnetic field electromagnetic wave magnetic field therapies |
url |
http://www.sciencedirect.com/science/article/pii/S2214031X16302790 |
work_keys_str_mv |
AT erikiwaldorff pulsedelectromagneticfieldapplicationsacorporateperspective AT nianlizhang pulsedelectromagneticfieldapplicationsacorporateperspective AT jamestryaby pulsedelectromagneticfieldapplicationsacorporateperspective |
_version_ |
1725139368501313536 |